K+S stock: EBITDA outlook midpoint rises after mixed Q3
Zalando stock: BlackRock raises total position to 5.83 percent
Iberdrola stock expands East Anglia offshore wind operations
BEX Announces WebID Integration to Strengthen Digital Identity Verification
UniCredit stock lifts outlook as Commerzbank plan advances
Inwit stock holds guidance despite weaker third-quarter results
Richemont stock weighs possible De Beers role after Botswana backs bid
Knorr-Bremse stock holds outlook as Rail orders miss expectations
Ariana Grande made her first TV appearance on Tonight Show 8 November
Siemens stock jumps as orders surge 58% in fiscal Q4
Fresenius stock gains as FMC sale raises EUR 524 million
Trane Technologies stock awaits Baird conference with management
Investor AB stock shifts focus to portfolio execution
Umicore stock: 450 million euros set for Hoboken expansion
Fresenius Medical Care stock: 500 million euro bond placed
Saint-Gobain stock advances Aviles furnace project after permit
Three Days Grace wrap Alienation Tour in Inglewood on 22 November
Grifols stock: Board backs US business IPO to reduce debt
Porr stock gains attention after PLN 539m Poland contract
Nordex stock in focus after C1 Connections acquisition deal
Stabilus stock faces lower 2030 revenue target of EUR 1.5 billion
Nibe Industrier stock faces margin test ahead of Q3 report
Prosus stock: Core profit doubles as e-commerce pivot accelerates
Orlen stock resets LNG strategy after QatarEnergy contract ends
Unipol stock faces solvency test as Berenberg keeps target
LEG Immobilien stock gains after AFFO growth and 2027 outlook
Talanx stock in focus after record profit and higher outlook
NatWest stock narrows overseas bond-market role
Ottobock stock posts Q3 growth as reimbursement pressure builds
Seagate stock in focus after FireCuda Forge hybrid drive launch
Sanofi stock: $1.9bn Dren Bio deal targets autoimmune diseases
MTU Aero Engines stock weighs cash growth against supply risks
Santander Bank Polska stock tied to Poland growth fund investment
Novartis stock faces FDA review over Zolgensma tumor risk